44
hBACE54
BACE1 Wild-type human BACE driven by the murine Thy1 promoter.
45
htau
MAPT
Double mutant mice were generated by mating mice that express human tau (8c mice) (Duff et al. 2000), with tau knockout mice that have a targeted disruption of exon one of tau (Tucker et al. 2001). Then backcrossed to obtain mice that are homozygous for disrupted murine MAPT while carrying the human tau transgene. Transgenic mice overexpressing a human tau isoform 383 amino acids long with 4 microtubule-binding repeat domains and without N-terminal inserts (4R/0N). Site-directed mutagenesis was used to introduce the P301S mutation. Transgene is under the control of the neuron-specific murine Thy-1 promoter. Transgene expressing wild-type human BACE1 driven by the
46
hTau.P301S
MAPT
47
Human-BACE1 BACE1 mouse thy1 promoter.
48
J20 (PDGFAPPSw,Ind)
APP
Transgene expresses human APP with the Swedish (K670N/M671L) and Indiana (V717F) mutations under the control of the human platelet derived growth factor-β (PDGF-β) promoter.
49
JNPL3(P301L) MAPT driven by the mouse prion promoter.
Transgene for human MAPT (4R0N) with the P301L mutation
50
mThy1hAPP751 (Line 41)
APP
The transgene over-expresses the mutant human amyloid protein precursor (751 isoform), which bears both the Swedish (K670N/M671L) and the London (V717I) mutations, under the control of the murine Thy1 promoter.
51 52 53
NSE-ApoE3 NSE-ApoE4
APOE
ApoE3 minigene driven by the rat neuron-specific enolase promoter. The ApoE4 minigene driven by the rat neuron-specific enolase promoter.
APOE
Transgene containing human PSEN2 carrying the N141I NSEPSEN2 mutation driven by the neuron-specific enolase (NSE) promoter. hPS2(N141I)
54
PDAPP(line10 APP 9) PDGFAPPSw,Ind (line J9)
A PDGF-driven human APP minigene with the V717F (Indiana) mutation. The construct contained APP introns 6-8 allowing alternative splicing of exons 7 and 8. Transgene expresses human APP with the Swedish (K670N/M671L) and Indiana (V717F) mutations under the control of the human platelet derived gro
wth factor-β (PDGF-β) promoter.
55
APP

Regimen Summary of Peptide Medicines for Alzheimer’ Disease (AD) Treatment ---Summarized peptide regimen for in vivo AD study Animal Study Model 3xTg-AD...
第二节 阿尔茨海默病(Alzheimer's disease,AD)阿尔茨海默病(Alzheimer's disease,AD) ,是发生于老年和老年前期、以 进行性认知功能障碍和行为损害为特征的中枢...
Medicines for Alzheimer’ Disease (AD) Treatment ---Summarized peptide regimen for in vivo AD study Animal Study Model 3xTg-AD Transgenic Mice Medicine ?...
阿尔茨海默病(Alzheimer’SDisease,AD)与动力相关蛋白1(dynamin—relatedprotein1,Drp1)_基础医学_医药卫生_专业资料。第3 0卷第 2期 201 3年 4月 生物学...
让我们向江教练致敬,并祝老年痴呆症患者早日康复! 治疗老年痴呆症的小偏方所谓的老年痴呆症,又称阿尔茨海默病(alzheimer's disease,ad)是发生在老年期及老年前期...
b.老年痴呆病 老年性痴呆病,分为阿尔茨海默病(Alzheimer’sdisease,AD)和血管性痴呆(VD) ,是一 种发病于老年期前后的原发性大脑退行性疾病。 近年来老年性痴呆...
老年痴呆症的护理 老年痴呆症又称阿尔茨海默病 (Alzheimer's disease,AD) 是发生在老年期及老年前期的一种 原发性退行性脑病, 指的是一种持续性高级神经功能...
In order to study AD pathology and develop AD ...Using Tg6799 as a mouse model for AD research ...(Alzheimer’s disease,AD)又称老年痴呆症,是一...
Alzheimer's disease 老年痴呆症Alzheimer's disease 老年痴呆症隐藏>> review article Pathways towards and away from Alzheimer’s disease Mark P. Mattson ...
老年痴呆症,又称阿尔茨海默病 (Alzheimer's disease,AD) 是发生在老年期 及老年前期的一种原发性退行性脑病,指 的是一种持续性高级神经功能活动障碍, 即在没...
热门文档